53 articles in this topic
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
French study explores how tiny cellular packages in blood could predict cancer recurrence and guide treatment decisions.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Phase II trial tested nivolumab with or without ipilimumab in 164 patients with metastatic sarcoma that couldn't be surgically removed.
French researchers test intraperitoneal nivolumab after surgery and heated chemotherapy for advanced ovarian cancer patients.
Phase 3 trial compared therapeutic vaccine OSE2101 to chemotherapy in 219 lung cancer patients after immunotherapy failure.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
